軟組織再生修復市場の競合動向

Abstract

Market Intelligence

In 2004, the US soft tissue repair market was valued at nearly $380 million. Driven primarily by product innovation, favorable demographics, and the overal behavioral adaptaion of physicians towards using biomaterials in soft tissue repair procedures. The market will grow to over $635 million by 2009. The hernia market comprised the largest market segment while the US and PFR markets will groww the fastest over the forcast period.

Table of Contents

TABLE OF CONTENTS

LIST OF EXHIBITS

METHODOLOGY

1.0 GLOBAL SOFT TISSUE REPAIR MARKET

• 1.1 US Soft Tissue Repair Market
• 1.2 European Soft Tissue Repair Market
• 1.3 Japanese Soft Tissue Repair Market
• 1.4 Competitive Analysis

2.0 C.R. BARD

• 2.1 Company Overview
• 2.2 Recent Events/Strategy
• 2.3 Products Offered
• 2.4 Global Sales Performance
  • 2.4.1 US
  • 2.4.2 Europe
  • 2.4.3 Japan
• 2.5 S.W.O.T. Analysis
  • 2.5.1 Strengths
  • 2.5.2 Weaknesses
  • 2.5.3 Opportunities
  • 2.5.4 Threats

3.0 GYNECARE

• 3.1 Company Overview
• 3.2 Recent Events/Strategy
• 3.3 Products Offered
• 3.4 Global Sales Performance
  • 3.4.1 US
  • 3.4.2 Europe
  • 3.4.3 Japan
• 3.5 S.W.O.T. Analysis
  • 3.5.1 Strengths
  • 3.5.2 Weaknesses
  • 3.5.3 Opportunities
  • 3.5.4 Threats

4.0 W.L. GORE

• 4.1 Company Overview
• 4.2 Recent Events/Strategy
• 4.3 Products Offered
• 4.4 Global Sales Performance
  • 4.4.1 US
  • 4.4.2 Europe
  • 4.4.3 Japan
• 4.5 S.W.O.T. Analysis
  • 4.5.1 Strengths
  • 4.5.2 Weaknesses
  • 4.5.3 Opportunities
  • 4.5.4 Threats

5.0 ETHICON

• 5.1 Company Overview
• 5.2 Recent Events/Strategy
• 5.3 Products Offered
• 5.4 Global Sales Performance
  • 5.4.1 US
  • 5.4.2 Europe
  • 5.4.3 Japan
• 5.5 S.W.O.T. Analysis
  • 5.5.1 Strengths
  • 5.5.2 Weaknesses
  • 5.5.3 Opportunities
  • 5.5.4 Threats

6.0 AMERICAN MEDICAL SYSTEMS

• 6.1 Company Overview
• 6.2 Recent Events/Strategy
• 6.3 Products Offered
• 6.4 Global Sales Performance
  • 6.4.1 US
  • 6.4.2 Europe
  • 6.4.3 Japan
• 6.5 S.W.O. T. Analysis
  • 6.5.1 Strengths
  • 6.5.2 Weaknesses
  • 6.5.3 Opportunities
  • 6.5.4 Threats

7.0 SYNOVIS LIFE TECHNOLOGIES

• 7.1 Company Overview
• 7.2 Recent Events/Strategy
• 7.3 Products Offered
• 7.4 Global Sales Performance
  • 7.4.1 US
  • 7.4.2 Europe
• 7.5 S.W.O.T. Analysis
  • 7.5.1 Strengths
  • 7.5.2 Weaknesses
  • 7.5.3 Opportunities
  • 7.5.4 Threats

8.0 BOSTON SCIENTIFIC

• 8.1 Company Overview
• 8.2 Recent Events/Strategy
• 8.3 Products Offered
• 8.4 Global Sales Performance
• 8.5 S.W.O. T. Analysis
  • 8.5.1 Strengths
  • 8.5.2 Weaknesses
  • 8.5.3 Opportunities
  • 8.5.4 Threats

9.0 SOFRADIM

• 9.1 Company Overview
• 9.2 Recent Events/Strategy
• 9.3 Products Offered
• 9.4 Global Sales Performance
  • 9.4.1 US
  • 9.4.2 Europe
• 9.5 S.W.O. T. Analysis
  • 9.5.1 Strengths
  • 9.5.2 Weaknesses
  • 9.5.3 Opportunities
  • 9.5.4 Threats

10.0 MENTOR

• 10.1 Company Overview
• 10.2 Recent Events/Stra tegy
• 10.3 Products Offered
• 10.4 Glob al Sales Performance
  • 10.4.1 US
  • 10.4.2 Europe
• 10.5 S.W.O. T. Analysis
  • 10.5.1 Strengths
  • 10.5.2 Weaknesses
  • 10.5.3 Opportunities
  • 10.5.4 Threats

11.0 COOK

• 11.1 Company Overview
• 11.2 Recent Events/Strategy
• 11.3 Products Offered
• 11.4 Global Sales Performance
  • 11.4.1 US
  • 11.4.2 Europe
  • 11.4.3 Japan
• 11.5 S.W.O.T. Analysis
  • 11.5.1 Strengths
  • 11.5.2 Weaknesses
  • 11.5.3 Opportunities
  • 11.5.4 Threats

APPENDIX A: MRG ACRONYMS AND INITIALISMS